Join the Saphris group to help and get support from people like you.
Saphris News
Actavis Receives FDA Approval of Saphris for Pediatric Patients with Bipolar I Disorder
DUBLIN, March 13, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for Saphris...
FDA Medwatch Alert: Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions
[Posted 09/01/2011] ISSUE: FDA notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine maleate). The Contraindications,...
Further information
Related condition support groups
Schizophrenia, Bipolar Disorder